ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-pxvi.xmlNCCN News2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-pxvi.pdf2026-04-18NCCN Newshttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-pxxxvii.xmlOncology Research Program2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-pxxxvii.pdf2026-04-18Oncology Research Programhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p643.xmlInternational Adaptations of NCCN Clinical Practice Guidelines in Oncology2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p643.pdf2026-04-18International Adaptations of NCCN Clinical Practice Guidelines in Oncologyhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p621.xmlMelanoma, Version 4.20142026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p621.pdf2026-04-18Melanoma, Version 4.2014https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p630.xmlSurvivorship: Sleep Disorders, Version 1.20142026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p630.pdf2026-04-18Survivorship: Sleep Disorders, Version 1.2014https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p611.xml BRAFV600E -Mutant Melanoma Presenting With Cardiac Involvement2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p611.pdf2026-04-18 BRAFV600E -Mutant Melanoma Presenting With Cardiac Involvementhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p605.xmlPart 3: Abstracts From the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p605.pdf2026-04-18Part 3: Abstracts From the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p603.xmlManaging the Fruits of Our Success2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p603.pdf2026-04-18Managing the Fruits of Our Successhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p657.xmlShould the ASCO/ASH Guidelines for the Use of Intravenous Iron in Cancer- and Chemotherapy-Induced Anemia Be Updated?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p657.pdf2026-04-18Should the ASCO/ASH Guidelines for the Use of Intravenous Iron in Cancer- and Chemotherapy-Induced Anemia Be Updated?https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p686.xmlProstate Cancer, Version 2.20142026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p686.pdf2026-04-18Prostate Cancer, Version 2.2014https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p719.xmlNeuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical Outcomes2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p719.pdf2026-04-18Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical Outcomeshttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p665.xmlClinical Discussion of the Management of Anaplastic Oligodendroglioma/Oligoastrocytoma (Both Codeleted and Nondeleted)2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p665.pdf2026-04-18Clinical Discussion of the Management of Anaplastic Oligodendroglioma/Oligoastrocytoma (Both Codeleted and Nondeleted)https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p673.xmlPatient Attitudes and Issues in Colon Cancer Screening2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p673.pdf2026-04-18Patient Attitudes and Issues in Colon Cancer Screeninghttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p735.xmlUnderserved Topics in Oncology: The Role of Physical Activity in Improving Quality of Life and Decreasing Recurrence Risk in Patients With Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p735.pdf2026-04-18Underserved Topics in Oncology: The Role of Physical Activity in Improving Quality of Life and Decreasing Recurrence Risk in Patients With Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p727.xmlIntermittent Versus Continuous Androgen Deprivation Therapy2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5/article-p727.pdf2026-04-18Intermittent Versus Continuous Androgen Deprivation Therapyhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p750.xmlGenomic Analysis of Breast Cancer Heralds a Changing Treatment Paradigm2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p750.pdf2026-04-18Genomic Analysis of Breast Cancer Heralds a Changing Treatment Paradigmhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p745.xmlThe Affordable Care Act: Where Are We Now? An NCCN Roundtable2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p745.pdf2026-04-18The Affordable Care Act: Where Are We Now? An NCCN Roundtablehttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p743.xmlAdvancing the Standard of Cancer Care in 20142026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p743.pdf2026-04-18Advancing the Standard of Cancer Care in 2014https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p764.xmlAdvances in the Treatment of Non-Small Cell Lung Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p764.pdf2026-04-18Advances in the Treatment of Non-Small Cell Lung Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p773.xmlNew Developments in the Treatment of Castration-Resistant Prostate Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p773.pdf2026-04-18New Developments in the Treatment of Castration-Resistant Prostate Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p768.xmlPoint/Counterpoint: Early Detection of Prostate Cancer: Do the Benefits Outweigh the Consequences?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p768.pdf2026-04-18Point/Counterpoint: Early Detection of Prostate Cancer: Do the Benefits Outweigh the Consequences?https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p759.xmlTreatment of Metastatic Breast Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p759.pdf2026-04-18Treatment of Metastatic Breast Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p777.xmlNCCN Roundtable: Talking to Children About Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p777.pdf2026-04-18NCCN Roundtable: Talking to Children About Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p817.xmlMonitoring Molecular Response to Tyrosine Kinase Therapy in Chronic Myelogenous Leukemia2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p817.pdf2026-04-18Monitoring Molecular Response to Tyrosine Kinase Therapy in Chronic Myelogenous Leukemiahttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p797.xmlGuidelines for NHL: Updates to the Management of Diffuse Large B-Cell Lymphoma and New Guidelines for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders and T-Cell Large Granular Lymphocytic Leukemia2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p797.pdf2026-04-18Guidelines for NHL: Updates to the Management of Diffuse Large B-Cell Lymphoma and New Guidelines for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders and T-Cell Large Granular Lymphocytic Leukemiahttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p813.xmlNCCN Bone Health Task Force: Key Recommendations2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p813.pdf2026-04-18NCCN Bone Health Task Force: Key Recommendationshttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p793.xmlTargeted Agents: Management of Dermatologic Toxicities2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p793.pdf2026-04-18Targeted Agents: Management of Dermatologic Toxicitieshttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p808.xmlMultiple Myeloma: Advances Reported in 2013 Are Useful in the Clinic2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p808.pdf2026-04-18Multiple Myeloma: Advances Reported in 2013 Are Useful in the Clinichttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p801.xmlChronic Lymphocytic Leukemia: State of the Art and Beyond2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p801.pdf2026-04-18Chronic Lymphocytic Leukemia: State of the Art and Beyondhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p781.xmlOptimizing Surveillance and Balancing Evidence With Patient Expectations2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p781.pdf2026-04-18Optimizing Surveillance and Balancing Evidence With Patient Expectationshttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p789.xmlOptimal Treatment of Unresectable Nonmelanoma Skin Cancers2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p789.pdf2026-04-18Optimal Treatment of Unresectable Nonmelanoma Skin Cancershttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p785.xmlAgents Make “Preferred List” in Metastatic Melanoma2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p785.pdf2026-04-18Agents Make “Preferred List” in Metastatic Melanomahttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p821.xmlTreatment Strategies for Myeloid Growth Factors and Intravenous Iron: When, What, and How?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p821.pdf2026-04-18Treatment Strategies for Myeloid Growth Factors and Intravenous Iron: When, What, and How?https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p825.xmlNCCN Guidelines for Survivorship Expanded to Address Two Common Conditions2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p825.pdf2026-04-18NCCN Guidelines for Survivorship Expanded to Address Two Common Conditionshttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p838.xmlInternational Adaptation and Use of NCCN Guidelines2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p838.pdf2026-04-18International Adaptation and Use of NCCN Guidelineshttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p836.xmlDon’t Neglect Cultural Diversity in Oncology Care2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p836.pdf2026-04-18Don’t Neglect Cultural Diversity in Oncology Carehttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p833.xmlCommon Controversies in the Management of Gallbladder Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p833.pdf2026-04-18Common Controversies in the Management of Gallbladder Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p829.xmlNCCN Increases the Emphasis on Genetic/Familial High-Risk Assessment in Colorectal Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/5S/article-p829.pdf2026-04-18NCCN Increases the Emphasis on Genetic/Familial High-Risk Assessment in Colorectal Cancer